New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
08:18 EDTSGMOSangamo price target raised to $27 from $22 at Wedbush
Wedbush raised its price target for Sangamo BioSciences to $27 saying the phase 1 results published in the New England Journal of Medicine suggest that the company's ZFN approach to treating HIV has broad acceptance in the medical and scientific communities. The firm reiterats an Outperform rating on the stock.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:17 EDTSGMOLeerink to hold a conference
Subscribe for More Information
February 9, 2016
19:18 EDTSGMOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Limelight Networks (LLNW), up 20%... Akamai Technologies (AKAM), up 15.7%... Marketo (MKTO), up 9.9%... Paycom Software (PAYC), up 13.8%... A10 Networks (ATEN), up 7.3%... Prospect Capital (PSEC), up 8.6%... Nuance Communications (NUAN), up 6.5%... Panera Bread (PNRA), up 2.8%. ALSO HIGHER: Empire District Electric (EDE), up 14.8% after Algonquin Power will acquire the company for $34.00 per share. DOWN AFTER EARNINGS: SolarCity (SCTY), down 32.6%... LeapFrog (LF), down 2%... Orion Energy Systems (OESX), down 23.8%... Seattle Genetics (SGEN), down 3.6%... Sangamo Biosciences (SGMO), down 7.1%... Disney (DIS), down 3.4%... Demandware (DWRE), down 2.6%. ALSO LOWER: Sunrun (RUN) is down 6.9%, Solaredge Technologies (SEDG) is down 6.6%, SunEdison (SUNE) is down 5.9%, Canadian Solar (CSIQ) is down 2.9%, SunPower (SPWR) is down 2.9%, and Tesla (TSLA) is down 2.2% following SolarCity's fourth quarter results.
16:08 EDTSGMOSangamo sees FY16 revenue $20M-$25M, consensus $34.23M
Subscribe for More Information
16:07 EDTSGMOSangamo reports Q4 EPS (20c), consensus (21c)
Subscribe for More Information
February 8, 2016
07:06 EDTSGMOSangamo announces FDA clearance of IND application for SB-318
Subscribe for More Information
February 2, 2016
08:36 EDTSGMOPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use